Catalyst Pharmaceuticals Stock Today
| CPRX Stock | USD 21.48 0.36 1.70% |
Performance3 of 100
| Odds Of DistressLess than 3
|
Catalyst Pharmaceuticals is trading at 21.48 as of the 24th of November 2024; that is 1.70 percent increase since the beginning of the trading day. The stock's open price was 21.12. Catalyst Pharmaceuticals has a very small chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for Catalyst Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of October 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of November 2006 | Category Healthcare | Classification Health Care |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. The company has 119.27 M outstanding shares of which 6.01 M shares are currently shorted by private and institutional investors with about 8.2 trading days to cover. More on Catalyst Pharmaceuticals
Moving against Catalyst Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Catalyst Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Richard MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCatalyst Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Catalyst Pharmaceuticals' financial leverage. It provides some insight into what part of Catalyst Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Catalyst Pharmaceuticals (CPRX) is traded on NASDAQ Exchange in USA. It is located in 355 Alhambra Circle, Coral Gables, FL, United States, 33134 and employs 167 people. Catalyst Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.56 B. Catalyst Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 119.27 M outstanding shares of which 6.01 M shares are currently shorted by private and institutional investors with about 8.2 trading days to cover.
Catalyst Pharmaceuticals currently holds about 220.79 M in cash with 143.6 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.15.
Check Catalyst Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCatalyst Pharmaceuticals holds a total of 119.27 Million outstanding shares. The majority of Catalyst Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Catalyst Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Catalyst Pharmaceuticals. Please pay attention to any change in the institutional holdings of Catalyst Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Catalyst Ownership Details
Catalyst Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Royce & Associates, Lp | 2024-09-30 | 2 M | |
| Northern Trust Corp | 2024-09-30 | 1.4 M | |
| Boston Partners Global Investors, Inc | 2024-09-30 | 1.3 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 1.2 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.2 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.1 M | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.1 M | |
| Kennedy Capital Management Inc | 2024-09-30 | 1 M | |
| Blackrock Inc | 2024-06-30 | 18.7 M | |
| Vanguard Group Inc | 2024-09-30 | 8 M |
Catalyst Pharmaceuticals Historical Income Statement
Catalyst Stock Against Markets
Catalyst Pharmaceuticals Corporate Management
| Philip Schwartz | Co Sec | Profile | |
| CMA CPA | VP, Officer | Profile | |
| Pete Sr | Vice Sales | Profile | |
| Mary Coleman | VP Relations | Profile | |
| Stanley MD | Senior Discovery | Profile | |
| Gary MD | Chief Officer | Profile |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.